Drug intelligence / Profile preview

ST-401

Development stage: Preclinical
Lead developer: Ceylon Biomedical
Modality: Small Molecules
Administration: Parenteral

Overview

ST-401 is a brain-penetrant small molecule that acts as a mild inhibitor of microtubule (MT) assembly. Unlike traditional microtubule-targeting agents (MTAs) that disrupt mitosis, ST-401 kills glioblastoma (GBM) cells during interphase by disrupting mitochondrial energy supply. It binds to the colchicine site of alpha,beta-tubulin, inducing a unique structural stabilization that triggers mitochondrial fission through the activation of Dynamin-related protein 1 (Drp1). ST-401 has demonstrated significant in vivo antitumor activity in glioblastoma mouse models and is being developed for the treatment of brain tumors. Its active enantiomer is identified as ST-403.

Other names: ST401ST-401ST 401

Targets

TUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on ST-401.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ST-401.

Explore the full profile